{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T19:28:44Z","timestamp":1744054124569,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40121-020-00319-0","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T13:03:57Z","timestamp":1595423037000},"page":"641-656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies"],"prefix":"10.1007","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct01830855","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01352845","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Johannes","family":"Beeslaar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Absalon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph J.","family":"Eiden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Balmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon L.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Pregaldien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Radley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Maansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Ginis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"319_CR1","doi-asserted-by":"crossref","unstructured":"Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. Available at: https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr6202a1.htm. Accessed 3 Feb 2020.","DOI":"10.15585\/mmwr.rr6909a1"},{"key":"319_CR2","unstructured":"Centers\u00a0for\u00a0Disease\u00a0Control\u00a0and\u00a0Prevention. Enhanced Meningococcal Disease Surveillance Report, 2018. Available at: https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report-2018.pdf. Accessed 7 Jan 2020."},{"key":"319_CR3","unstructured":"European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases. Available at: https:\/\/ecdc.europa.eu\/en\/surveillance-atlas-infectious-diseases. Accessed 14 Apr 2020."},{"key":"319_CR4","doi-asserted-by":"publisher","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","volume":"30","author":"D Pace","year":"2012","unstructured":"Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30:B3\u20139.","journal-title":"Vaccine."},{"key":"319_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(06)67932-4","volume":"367","author":"MJ Thompson","year":"2006","unstructured":"Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367:397\u2013403.","journal-title":"Lancet"},{"key":"319_CR6","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1093\/cid\/civ028","volume":"60","author":"M Sadarangani","year":"2015","unstructured":"Sadarangani M, Scheifele DW, Halperin SA, et al. Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study. Clin Infect Dis. 2015;60:e27\u201335.","journal-title":"Clin Infect Dis"},{"key":"319_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","volume":"16","author":"R Borrow","year":"2017","unstructured":"Borrow R, Alarcon P, Carlos J, et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16:313\u201328.","journal-title":"Expert Rev Vaccines."},{"key":"319_CR8","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/S1473-3099(15)00217-0","volume":"15","author":"S Sridhar","year":"2015","unstructured":"Sridhar S, Greenwood B, Head C, et al. Global incidence of serogroup B invasive meningococcal disease: a systematic review. Lancet Infect Dis. 2015;15:1334\u201346.","journal-title":"Lancet Infect Dis."},{"key":"319_CR9","unstructured":"European Centre for Disease Prevention and Control. Annual Epidemiological Report 2016 \u2013 Invasive meningococcal disease. http:\/\/ecdc.europa.eu\/en\/healthtopics\/meningococcal\/Pages\/Annual-epidemiological-report-2016.aspx. Accessed 24 Apr 2017."},{"key":"319_CR10","unstructured":"Menveo\u00ae (meningococcal [groups A, C, Y and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine). Full Prescribing Information, Novartis, Sovicille, Italy, 2013."},{"key":"319_CR11","unstructured":"Menactra\u00ae (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine). Full Prescribing Information, Sanofi Pasteur Inc., Swiftwater, PA, 2018."},{"key":"319_CR12","unstructured":"Pfizer Canada Inc. Nimenrix Product Monograph. Kirkland, QC: Pfizer Canada Inc; 2016."},{"key":"319_CR13","unstructured":"Trumenba\u00ae (meningococcal group B vaccine). Full Prescribing Information, Wyeth Pharmaceuticals Inc (a subsidiary of Pfizer Inc), Philadelphia, PA, 2018."},{"key":"319_CR14","unstructured":"Bexsero\u00ae (Meningococcal Group B Vaccine). Full Prescribing Information, GSK Vaccines, Srl, Siena, Italy, 2018."},{"key":"319_CR15","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.vaccine.2003.10.005","volume":"22","author":"J Bruge","year":"2004","unstructured":"Bruge J, Bouveret-Le Cam N, Danve B, Rougon G, Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine. 2004;22:1087\u201396.","journal-title":"Vaccine."},{"key":"319_CR16","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","volume":"126","author":"FA Wyle","year":"1972","unstructured":"Wyle FA, Artenstein MS, Brandt BL, et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis. 1972;126:514\u201321.","journal-title":"J Infect Dis"},{"key":"319_CR17","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","volume":"23","author":"R Borrow","year":"2005","unstructured":"Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection\u2014serum bactericidal antibody activity. Vaccine. 2005;23:2222\u20137.","journal-title":"Vaccine."},{"key":"319_CR18","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","volume":"129","author":"I Goldschneider","year":"1969","unstructured":"Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307\u201326.","journal-title":"J Exp Med."},{"key":"319_CR19","doi-asserted-by":"publisher","first-page":"e00036-18","DOI":"10.1128\/mBio.00036-18","volume":"9","author":"LK McNeil","year":"2018","unstructured":"McNeil LK, Donald RGK, Gribenko A, et al. Predicting the susceptibility of meningococcal serogroup B isolates to bactericidal antibodies elicited by bivalent rLP2086, a novel prophylactic vaccine. MBio. 2018;9:e00036-18.","journal-title":"MBio."},{"key":"319_CR20","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1128\/CVI.00027-10","volume":"17","author":"J Lucidarme","year":"2010","unstructured":"Lucidarme J, Comanducci M, Findlow J, et al. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol. 2010;17:919\u201329.","journal-title":"Clin Vaccine Immunol"},{"key":"319_CR21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.4161\/hv.7.6.15482","volume":"7","author":"D Toneatto","year":"2011","unstructured":"Toneatto D, Ismaili S, Ypma E, et al. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin. 2011;7:646\u201353.","journal-title":"Hum Vaccin."},{"key":"319_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1128\/MMBR.00056-12","volume":"77","author":"LK McNeil","year":"2013","unstructured":"McNeil LK, Zagursky R, Shuo L, et al. The role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev. 2013;77:234\u201352.","journal-title":"Microbiol Mol Biol Rev"},{"key":"319_CR23","unstructured":"Neisseria Factor H binding protein sequence typing. Available at: https:\/\/pubmlst.org\/neisseria\/fHbp\/. Accessed 11 Oct 2018."},{"key":"319_CR24","unstructured":"US Food and Drug Administration. Summary Basis for Regulatory Action. Available at: https:\/\/wayback.archive-it.org\/7993\/20190425012126\/https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM424125.pdf. Accessed 8 Jul 2020."},{"key":"319_CR25","unstructured":"European Medicines Agency. EPAR Summary for the Public: Trumenba. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/004051\/WC500228998.pdf. Accessed 12 July 2019."},{"key":"319_CR26","unstructured":"Pfizer Canada Inc. Product monograph: TrumenbaTM. Pfizer Canada Inc. https:\/\/pdf.hres.ca\/dpd_pm\/00041515.PDF. Accessed 11 Oct 2018."},{"key":"319_CR27","unstructured":"Australian Government Department of Health Therapeutic Goods Administration. Prescription Medicines: Registration of New Chemical Entities in Australia. https:\/\/www.tga.gov.au\/prescription-medicines-registration-new-chemical-entities-australia. Accessed 11 Oct 2018."},{"key":"319_CR28","unstructured":"Trumenba (MenB-FHbp; bivalent rLP2086). Full Prescribing Information, Pfizer Chile S.A., Santiago, Chile, 2016."},{"key":"319_CR29","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1056\/NEJMoa1614474","volume":"377","author":"L Ostergaard","year":"2017","unstructured":"Ostergaard L, Vesikari T, Absalon J, et al. A bivalent meningococcal B vaccine in adolescents and young adults. N Engl J Med. 2017;377:2349\u201362.","journal-title":"N Engl J Med"},{"key":"319_CR30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4161\/hv.34293","volume":"11","author":"GW Zlotnick","year":"2015","unstructured":"Zlotnick GW, Jones TR, Liberator P, et al. The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B disease. Hum Vaccine Immunother. 2015;11:5\u201313.","journal-title":"Hum Vaccine Immunother."},{"key":"319_CR31","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","volume":"24","author":"R Borrow","year":"2006","unstructured":"Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization\u2013international meeting report Emory University, Atlanta, Georgia, United States, 16\u201317 March 2005. Vaccine. 2006;24:5093\u2013107.","journal-title":"Vaccine."},{"key":"319_CR32","doi-asserted-by":"publisher","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","volume":"27","author":"CE Frasch","year":"2009","unstructured":"Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine. 2009;27:B112\u20136.","journal-title":"Vaccine."},{"key":"319_CR33","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMra0906357","volume":"362","author":"LK Tan","year":"2010","unstructured":"Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010;362:1511\u201320.","journal-title":"N Engl J Med"},{"key":"319_CR34","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","volume":"72","author":"LD Fletcher","year":"2004","unstructured":"Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72:2088\u2013100.","journal-title":"Infect Immun"},{"key":"319_CR35","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1086\/600141","volume":"200","author":"E Murphy","year":"2009","unstructured":"Murphy E, Andrew L, Lee KL, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200:379\u201389.","journal-title":"J Infect Dis"},{"key":"319_CR36","doi-asserted-by":"publisher","first-page":"19490","DOI":"10.1073\/pnas.1013758107","volume":"107","author":"J Donnelly","year":"2010","unstructured":"Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA. 2010;107:19490\u20135.","journal-title":"Proc Natl Acad Sci USA."},{"key":"319_CR37","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1016\/j.vaccine.2015.04.015","volume":"33","author":"D Medini","year":"2015","unstructured":"Medini D, Stella M, Wassil J. MATS: global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine. 2015;33:2629\u201336.","journal-title":"Vaccine."},{"key":"319_CR38","unstructured":"Basta N, Wolfson J, Mahmoud A, et al. 4CMenB vaccine immunogenicity up to 1\u00a0year after vaccination among university students. Presented at: International Pathogenic Neisseria Conference, September 23\u201328, 2018; Asilomar, CA, USA."},{"key":"319_CR39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jinf.2017.05.015","volume":"75","author":"J Lucidarme","year":"2017","unstructured":"Lucidarme J, Lekshmi A, Parikh SR, et al. Frequent capsule switching in \u2018ultra-virulent\u2019 meningococci\u2014are we ready for a serogroup B ST-11 complex outbreak? J Infect. 2017;75:95\u2013103.","journal-title":"J Infect"},{"key":"319_CR40","doi-asserted-by":"publisher","first-page":"e1001027","DOI":"10.1371\/journal.ppat.1001027","volume":"6","author":"LA Lewis","year":"2010","unstructured":"Lewis LA, Ngampasutadol J, Wallace R, et al. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 2010;6:e1001027.","journal-title":"PLoS Pathog"},{"key":"319_CR41","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1128\/CVI.00055-11","volume":"18","author":"J Lucidarme","year":"2011","unstructured":"Lucidarme J, Tan L, Exley RM, et al. Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol. 2011;18:1002\u201314.","journal-title":"Clin Vaccine Immunol"},{"key":"319_CR42","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1016\/j.vaccine.2011.04.092","volume":"29","author":"X Wang","year":"2011","unstructured":"Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29:4739\u201344.","journal-title":"Vaccine."},{"key":"319_CR43","doi-asserted-by":"publisher","first-page":"7667","DOI":"10.1016\/j.vaccine.2010.09.038","volume":"28","author":"DA Ala\u2019Aldeen","year":"2010","unstructured":"Ala\u2019Aldeen DA, Flint M, Oldfield NJ, et al. Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage. Vaccine. 2010;28:7667\u201375.","journal-title":"Vaccine."},{"key":"319_CR44","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/21645515.2017.1264750","volume":"13","author":"RG Donald","year":"2017","unstructured":"Donald RG, Hawkins JC, Hao L, et al. Meningococcal serogroup B vaccines: estimating breadth of coverage. Hum Vaccine Immunother. 2017;13:255\u201365.","journal-title":"Hum Vaccine Immunother."},{"key":"319_CR45","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.vaccine.2018.11.073","volume":"37","author":"T Vesikari","year":"2019","unstructured":"Vesikari T, Ostergaard L, Beeslaar J, et al. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: a phase 3 extension study in adolescents. Vaccine. 2019;37:1710\u20131719.","journal-title":"Vaccine"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-020-00319-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-020-00319-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-020-00319-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T23:54:42Z","timestamp":1667519682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-020-00319-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["319"],"URL":"https:\/\/doi.org\/10.1007\/s40121-020-00319-0","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"type":"print","value":"2193-8229"},{"type":"electronic","value":"2193-6382"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"30 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}